Astrazeneca Company Profile

What is the competitive landscape for ASTRAZENECA

ASTRAZENECA has ninety-three approved drugs.

There are one hundred and eleven US patents protecting ASTRAZENECA drugs. There is one tentative approval on ASTRAZENECA drugs.

There are two thousand one hundred and eighty-one patent family members on ASTRAZENECA drugs in seventy countries and three hundred and fifty-eight supplementary protection certificates in twenty countries.

Summary for Astrazeneca

International Patents:	2181
US Patents:	111
Tradenames:	66
Ingredients:	61
NDAs:	93
Patent Litigation for Astrazeneca:	See patent lawsuits for Astrazeneca
PTAB Cases with Astrazeneca as patent owner:	See PTAB cases with Astrazeneca as patent owner

Drugs and US Patents for Astrazeneca

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	AQUASOL A	vitamin a	CAPSULE;ORAL	083080-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Astrazeneca	CALQUENCE	acalabrutinib	CAPSULE;ORAL	210259-001	Oct 31, 2017		RX	Yes	Yes
Astrazeneca	LYNPARZA	olaparib	TABLET;ORAL	208558-002	Aug 17, 2017		RX	Yes	Yes
Astrazeneca	TRUQAP	capivasertib	TABLET;ORAL	218197-002	Nov 16, 2023		RX	Yes	Yes	10,654,855
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes	9,181,549			Y

Expired US Patents for Astrazeneca

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014	6,858,576
Astrazeneca	DURANEST	epinephrine bitartrate; etidocaine hydrochloride	INJECTABLE;INJECTION	017751-006	Approved Prior to Jan 1, 1982	3,812,147
Astrazeneca	NEXIUM	esomeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022101-001	Feb 27, 2008	5,877,192*PED
Astrazeneca Lp	NEXIUM 24HR	esomeprazole magnesium	TABLET, DELAYED RELEASE;ORAL	207920-001	Nov 23, 2015	6,428,810*PED
Astrazeneca Ab	QTERN	dapagliflozin; saxagliptin hydrochloride	TABLET;ORAL	209091-001	Feb 27, 2017	RE44186

Paragraph IV (Patent) Challenges for ASTRAZENECA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	For Injection	20 mg/vial and 40 mg/vial		2009-11-23
	Injection	250 mg/mL, 1.2 mL and 2.4 mL prefilled syringe		2014-06-11
	Inhalation Suspension	0.25 mg/2 mL and 0.5 mg/2 mL		2005-09-15
	HydrochlorideExtended-release Tablets	2.5 mg/1000 mg		2018-10-29
	Delayed-release Capsules	20 mg		2007-03-19
	Extended-release Tablets	400 mg		2008-06-18
	Tablets	200 mg and 300 mg		2008-06-12
	Tablets	90 mg		2015-07-20
	Tablets	5 mg, 10 mg, 20 mg and 40 mg		2007-08-13
	Nasal Spray	0.032 mg (32 mcg)/spray		2007-05-14
	Tablets	25 mg		2005-08-12
	Delayed-release for Oral Suspension	2.5 mg and 5 mg		2018-09-24
	Tablets	100 mg, 200 mg and 300 mg		2006-02-21
	Injection	50 mg/mL, 2.5 mL and 5 mL syringe		2009-10-01
	Extended-release Tablets	5 mg/500 mg, 2.5 mg/1000 mg, and 5 mg/1000 mg		2013-07-31
	Inhalation Suspension	1 mg/2 mL		2010-05-28
	Tablets	2.5 mg and 5 mg		2013-07-31
	Delayed-release Tablets	20 mg		2012-03-30
	Extended-release Tablets	150 mg		2008-11-17
	Extended-release Tablets	50 mg		2008-10-17
	Tablets	60 mg		2015-09-30
	Tablets	500 mcg		2015-03-02
	Delayed-release	20 mg and 40 mg		2005-08-05
	Tablets	50 mg, 150 mg and 400 mg		2007-02-12

International Patents for Astrazeneca Drugs

Country	Patent Number	Estimated Expiration
France	19C1040
Germany	60020259
Malaysia	187088
Norway	20012725
Poland	3686193

Supplementary Protection Certificates for Astrazeneca Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2734522	2190009-7	Sweden		PRODUCT NAME: ACALABRUTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/20/1479 20201106
1685839	92292	Luxembourg		PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
1532149	CA 2013 00001	Denmark		PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6-DION ENANTIOMERER OG SALTE DERAF - SAERLIGT LINAGLIPTIN - I KOMBINATION MED METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/12/780/001-028 20120720
2734522	CA 2021 00007	Denmark		PRODUCT NAME: ACALABRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/20/1479 20201106
1606261	PA2010010,C1606261	Lithuania		PRODUCT NAME: ROFLUMILASTUM; REGISTRATION NO/DATE: EU/1/10/636/001-003 20100705

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Astral
• Astrazeneca
• Astrazeneca Ab
• Astrazeneca Lp

AstraZeneca's Competitive Landscape: Market Position, Strengths, and Strategic Insights

In the ever-evolving pharmaceutical industry, AstraZeneca stands as a formidable player, consistently pushing the boundaries of innovation and growth. As we delve into the competitive landscape surrounding this pharmaceutical giant, we'll explore its market position, strengths, and strategic insights that have propelled it to the forefront of the industry.

AstraZeneca's Market Position

AstraZeneca has solidified its position as a leading global biopharmaceutical company, known for its innovative approach to drug discovery and development[2]. With operations spanning over 100 countries, the company has established a strong global presence, allowing it to tap into diverse markets and cater to a broad range of patient needs[2].

Revenue Growth and Future Ambitions

AstraZeneca's market position is further strengthened by its impressive revenue growth. In 2023, the company reported total revenue of $45.8 billion, up from $44.4 billion in the previous year[1]. This growth trajectory has set the stage for even more ambitious goals. AstraZeneca has unveiled its bold vision to achieve $80 billion in total revenue by 2030, nearly doubling its current figures[1].

"Today AstraZeneca announces a new era of growth. In 2023 we delivered the ambitious $45 billion revenue goal set a decade ago. With the exciting growth of our innovative pipeline, which has the potential to transform millions of lives, we are now aiming for $80 billion by 2030." - Pascal Soriot, Chief Executive Officer, AstraZeneca[1]

This ambitious target underscores AstraZeneca's confidence in its pipeline and strategic direction, positioning it as a company with significant growth potential in the coming years.

Global Market Share

AstraZeneca's global market share is substantial, with the company ranking 8th globally based on prescription drug sales in 2023[5]. This positioning places AstraZeneca among the top-tier pharmaceutical companies worldwide, competing with industry giants like Pfizer, Merck, and GlaxoSmithKline.

AstraZeneca's Key Strengths

AstraZeneca's competitive edge in the pharmaceutical landscape is built on several key strengths that set it apart from its rivals.

Strong Product Portfolio

One of AstraZeneca's primary strengths lies in its robust and diverse product portfolio. The company boasts several blockbuster drugs across various therapeutic areas, including oncology, cardiovascular, renal, metabolism, respiratory, and immunology[3]. This diversification not only contributes to the company's financial stability but also positions it to address a wide range of medical needs.

Robust Research and Development Pipeline

AstraZeneca's commitment to innovation is evident in its strong R&D pipeline. The company invests heavily in research and development, with spending well above 20% of its revenues on R&D projects[5]. This focus on innovation has resulted in a pipeline of over 60 molecules in clinical development[3], promising a steady stream of new products in the coming years.

Global Presence and Market Reach

With operations in over 100 countries, AstraZeneca's global footprint is a significant strength[2]. This extensive reach allows the company to navigate diverse regulatory environments, tap into emerging markets, and maintain a strong presence in established pharmaceutical markets.

Strategic Partnerships and Collaborations

AstraZeneca has fostered strategic partnerships with academic institutions, research organizations, and other pharmaceutical companies[2]. These collaborations enhance the company's capabilities, accelerate drug development processes, and provide access to cutting-edge technologies and expertise.

Strategic Insights: AstraZeneca's Path Forward

AstraZeneca's strategic direction is shaped by several key insights and initiatives that are likely to drive its future growth and competitive position.

Focus on High-Growth Therapeutic Areas

AstraZeneca has strategically focused on high-growth therapeutic areas, particularly oncology. The company's oncology portfolio has shown impressive growth, with sales increasing by 20% in 2023[9]. This focus on areas with significant unmet medical needs positions AstraZeneca to capture growing market segments.

Emphasis on Personalized Medicine

AstraZeneca is at the forefront of personalized medicine, developing treatments tailored to individual patient profiles[2]. This approach not only improves patient outcomes but also differentiates AstraZeneca in an increasingly competitive market.

Expansion into Rare Diseases

The $39 billion acquisition of Alexion in 2021 marked AstraZeneca's strategic entry into the rare disease market[9]. This move has diversified the company's portfolio and opened up new growth opportunities in a specialized and potentially lucrative segment of the pharmaceutical industry.

Commitment to Sustainability

AstraZeneca's focus on sustainability and corporate social responsibility resonates with consumers and investors alike[2]. This commitment not only enhances the company's reputation but also aligns with growing global emphasis on sustainable business practices.

Navigating Challenges in the Competitive Landscape

While AstraZeneca's position is strong, the company faces several challenges in the competitive pharmaceutical landscape.

Patent Expirations

Like many pharmaceutical companies, AstraZeneca must navigate the challenge of patent expirations for key products. The upcoming patent expirations for blockbuster drugs like Farxiga and Tagrisso present a significant hurdle in maintaining revenue growth[9].

Intense Competition in Key Therapeutic Areas

AstraZeneca faces stiff competition in several of its key therapeutic areas, particularly in oncology[8]. As a relatively late entrant in some fields, the company must continually innovate to differentiate its offerings and capture market share.

Regulatory and Pricing Pressures

The pharmaceutical industry as a whole faces increasing regulatory scrutiny and pressure to control drug prices. AstraZeneca must navigate these challenges while maintaining profitability and funding its extensive R&D efforts.

AstraZeneca's Competitive Advantages

Several factors contribute to AstraZeneca's competitive edge in the pharmaceutical market:

Strong Brand Reputation

AstraZeneca has built a strong brand reputation over the years, known for delivering high-quality, innovative medicines[2]. This reputation instills trust among healthcare professionals, patients, and investors.

Diverse Geographic Revenue Stream

AstraZeneca's revenue is well-distributed geographically, with significant contributions from various regions. In 2023, the US market accounted for 44% of the company's total revenue, highlighting the importance of this key market while also demonstrating the company's global reach[10].

Effective Corporate Strategy

AstraZeneca's corporate strategy effectively aligns with changing market dynamics, focusing on areas with high unmet medical needs[7]. This strategic alignment positions the company to capitalize on emerging opportunities in the pharmaceutical landscape.

Future Outlook and Growth Strategies

Looking ahead, AstraZeneca's growth strategy centers on several key initiatives:

Ambitious Product Launch Plans

AstraZeneca plans to launch 20 new medicines by 2030, many with the potential to generate more than $5 billion in peak year revenues[1]. This aggressive pipeline strategy is central to the company's ambitious revenue growth targets.

Continued Investment in R&D

AstraZeneca remains committed to investing heavily in research and development, maintaining its position at the forefront of pharmaceutical innovation[5].

Strategic M&A and Partnerships

While organic growth is a priority, AstraZeneca's history suggests that strategic mergers, acquisitions, and partnerships will continue to play a role in expanding its capabilities and market reach[9].

Expansion in Emerging Markets

AstraZeneca is likely to continue its focus on expanding its presence in emerging markets, capitalizing on growing healthcare needs and increasing access to medicines in these regions.

Key Takeaways

• AstraZeneca holds a strong market position, ranking 8th globally in prescription drug sales.
• The company aims to achieve $80 billion in total revenue by 2030, driven by a robust pipeline and strategic focus on high-growth therapeutic areas.
• Key strengths include a diverse product portfolio, strong R&D capabilities, global presence, and strategic partnerships.
• Challenges include patent expirations, intense competition, and regulatory pressures.
• Future growth strategies center on ambitious product launches, continued R&D investment, strategic M&A, and expansion in emerging markets.

FAQs

1. What is AstraZeneca's current market position in the pharmaceutical industry? AstraZeneca ranks 8th globally based on prescription drug sales as of 2023, with a strong presence in key therapeutic areas such as oncology, cardiovascular, and respiratory diseases.

2. How does AstraZeneca plan to achieve its $80 billion revenue target by 2030? AstraZeneca plans to launch 20 new medicines by 2030, many with potential for over $5 billion in peak year revenues. The company will also continue investing in R&D and focus on high-growth therapeutic areas.

3. What are some of AstraZeneca's key competitive advantages? AstraZeneca's competitive advantages include a strong product portfolio, robust R&D pipeline, global presence, strategic partnerships, and a focus on personalized medicine and rare diseases.

4. How is AstraZeneca addressing the challenge of patent expirations? While specific strategies aren't detailed in the provided information, pharmaceutical companies typically address patent expirations through developing new drugs, extending existing patents through new formulations or indications, and diversifying their product portfolio.

5. What role does sustainability play in AstraZeneca's strategy? AstraZeneca has a strong commitment to sustainability and corporate social responsibility, which enhances its reputation and aligns with growing global emphasis on sustainable business practices.

Sources cited: [1] https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-deliver-80bn-revenue-by-2030.html [2] https://canvasbusinessmodel.com/blogs/competitors/astrazeneca-competitive-landscape [3] https://www.studentsassignmenthelp.co.uk/answers/astrazeneca-uk-swot-analysis/ [5] https://www.statista.com/topics/7584/astrazeneca/ [7] https://thestrategystory.com/blog/astrazeneca-swot-analysis/ [8] https://www.investing.com/news/swot-analysis/astrazenecas-swot-analysis-pharma-giants-stock-poised-for-growth-amid-challenges-93CH-3838445 [9] https://www.fiercepharma.com/pharma/astrazeneca-fast-track-growth-sets-target-revenue-80b-2030 [10] https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-invests-3bn-500mn-in-us.html